Cargando…
CD19 Targeted Low-Dose Rituximab Is Effective in the Management of Refractory Phospholipase A2 Receptor Antibody-Associated Membranous Nephropathy
Autores principales: | Ramachandran, Raja, Yadav, Ashok K., Kumar, Vinod, Gupta, Krishan L., Kohli, Harbir S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678839/ https://www.ncbi.nlm.nih.gov/pubmed/29142946 http://dx.doi.org/10.1016/j.ekir.2016.08.019 |
Ejemplares similares
-
Rituximab in Primary Membranous Nephropathy With Severe CKD
por: Naik, Sachin, et al.
Publicado: (2023) -
Rituximab in Patients With Primary Membranous Nephropathy With High Immunologic Risk
por: Naik, Sachin, et al.
Publicado: (2023) -
Two-Year Follow-up Study of Membranous Nephropathy Treated With Tacrolimus and Corticosteroids Versus Cyclical Corticosteroids and Cyclophosphamide
por: Ramachandran, Raja, et al.
Publicado: (2017) -
Infusion of autologous bone marrow mononuclear cells leads to transient reduction in proteinuria in treatment refractory patients with Idiopathic membranous nephropathy
por: Sengupta, Upal, et al.
Publicado: (2013) -
Long-Term Follow-Up of Cyclical Cyclophosphamide and Steroids Versus Tacrolimus and Steroids in Primary Membranous Nephropathy
por: Ramachandran, Raja, et al.
Publicado: (2021)